LSX-Blog.png

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

Realising the potential of cannabinoid-related the...

On 10-11 October 2018, investors, industry stakeholders, and senior executi...

Read More

Infographic: Spotlight on the US Life Sciences Sec...

Silicon Valley Bank’s mid-year report, Trends in Healthcare Investments and...

Read More

Accessing US Government Funds for Research and Dev...

The US Government has long been a significant source of funds for life scie...

Read More

Novoheart expands global presence to support comme...

Key learnings: Novoheart has developed human bioengineered heart constructs...

Read More

Carmell Therapeutics advances plasma-based product...

Key learnings: Carmell™ Therapeutics closed its Series B round in June 2017...

Read More

Interview with Inmedix’s Andrew J. Holman

Andrew J. Holman, Co-Founder and Chief Executive Officer at Inmedix, talks ...

Read More

Interview with PDL BioPharma’s Peter Garcia

Peter Garcia, Vice President and Chief Financial Officer at Nevada-based, p...

Read More

Interview with Heat Biologics’ John Prendergast

John Prendergast, Lead Independent Director at North Carolina-based Nasdaq-...

Read More

Winner’s spotlight: Verona Pharma

Key learnings: Verona Pharma won the Life Science IPO of the Year Award at ...

Read More

Transatlantic investment: barriers and benefits fo...

On Monday 5 February 2018, leading investors will come together in London t...

Read More

Investorview: Proactively Bridging The Early Stage...

Sinclair Dunlop, Managing Partner at Epidarex Capital Venture capital firm ...

Read More

Investorview: Dr Z Haroon on Julz Co’s recent inve...

Julz Co focuses on healthcare investments across the US, Europe, and Asia-P...

Read More

Add Your Response